{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-22-000139","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.031882+00:00","generated_at":"2026-06-22T07:11:18.500971+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunovant unveils next-gen FcRn inhibitor IMVT-1402; Q2 net loss $47.9M","bullets":["IMVT-1402 observed in animal study to have best-in-class IgG reduction with minimal albumin/LDL impact.","New batoclimab programs: Phase 2b in CIDP (start by end-2022) and Phase 2 in Graves' disease (early 2023).","Pro forma cash $476M after $70M October 2022 equity offering; cash runway into H2 2025.","Q2 net loss $47.9M ($0.41/sh) vs $37.7M ($0.35/sh) YoY; R&D expenses rose to $37.7M.","IMVT-1402 IND submission early 2023, initial data mid-2023; batoclimab MG and TED trials on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-22-000139","json":"https://secwatch.observer/filing/0001764013-22-000139.json","markdown":"https://secwatch.observer/filing/0001764013-22-000139.md","text":"https://secwatch.observer/filing/0001764013-22-000139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/0001764013-22-000139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/imvt-20221104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:11:18.500971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a9f440d90cd5bb9d2f6131c394f40c7b0f3deff","claim":"Immunovant, Inc. reported its fiscal second quarter and six months ended September 30, 2022 results: net income Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022, EPS $0.76 per common share.","evidence_excerpt":"Net loss was $47.9 million ($0.41 per common share) for the three months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/0001764013-22-000139-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its fiscal second quarter and six months ended September 30, 2022"},{"label":"Net income","value":"Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022"},{"label":"EPS","value":"$0.76 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7a9f440d90cd5bb9d2f6131c394f40c7b0f3deff","claim":"Immunovant, Inc. reported its fiscal second quarter and six months ended September 30, 2022 results: net income Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022, EPS $0.76 per common share.","evidence_excerpt":"Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/0001764013-22-000139-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its fiscal second quarter and six months ended September 30, 2022"},{"label":"Net income","value":"Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022"},{"label":"EPS","value":"$0.76 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}